Days after revealing a potential half-billion dollar collaboration in hemophilia with Pfizer (NYSE: PFE), US gene editing specialist Sangamo Therapeutics (Nasdaq: SGMO) announced that the US regulator has granted Fast Track designation to SB-525.
The company’s gene therapy candidate for hemophilia A, which forms part of the exclusive, global deal with Pfizer, is designed to deliver a synthetic, liver-specific promoter with a single infusion.
The decision means the company will have more frequent communication with the US Food and Drug Administration, which has also designated the therapy an Orphan Drug, in order to expedite the review process.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze